Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Elsevier 2023-12-01
Reeks:	Translational Oncology
Onderwerpen:	Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors
Online toegang:	http://www.sciencedirect.com/science/article/pii/S1936523323001857

Gelijkaardige items

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
door: Hana Garaj, et al.
Gepubliceerd in: (2024-01-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
door: Senar Ebinç, et al.
Gepubliceerd in: (2023-09-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
door: Wu L, et al.
Gepubliceerd in: (2021-02-01)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
door: Katarina Mirjačić Martinović, et al.
Gepubliceerd in: (2023-04-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
door: Dugan MM, et al.
Gepubliceerd in: (2024-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
door: Polsky David, et al.
Gepubliceerd in: (2004-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
door: Francesca Consoli, et al.
Gepubliceerd in: (2020-07-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
door: Jacek Calik, et al.
Gepubliceerd in: (2024-01-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
door: Justin C. Moser, et al.
Gepubliceerd in: (2019-12-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
door: Xiang Dan, et al.
Gepubliceerd in: (2024-04-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
door: I. V. SAMOILENKO, et al.
Gepubliceerd in: (2017-06-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
door: Ernesto Rossi, et al.
Gepubliceerd in: (2023-01-01)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
door: Lance Wollenberg, et al.
Gepubliceerd in: (2023-10-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
door: Bartoušková Marie, et al.
Gepubliceerd in: (2020-08-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
door: Yu. S. Shakh-Paronyants, et al.
Gepubliceerd in: (2023-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
door: Dahlia Fedele, et al.
Gepubliceerd in: (2024-01-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
door: Saba S. Shaikh, et al.
Gepubliceerd in: (2022-11-01)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
door: Milena Cavic, et al.
Gepubliceerd in: (2023-04-01)

Melanoma: BRAFi Rechallenge
door: Christoforos S. Kosmidis, et al.
Gepubliceerd in: (2023-05-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
door: Rozala Arko, et al.
Gepubliceerd in: (2022-07-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
door: Sarkisian S, et al.
Gepubliceerd in: (2018-08-01)

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
door: Lazaro Hiram Betancourt, et al.
Gepubliceerd in: (2021-07-01)

Current State of Target Treatment in BRAF Mutated Melanoma
door: Enrica Teresa Tanda, et al.
Gepubliceerd in: (2020-07-01)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
door: Marco Ghezzi, et al.
Gepubliceerd in: (2020-03-01)

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
door: Ahmed Temirak, et al.
Gepubliceerd in: (2025-02-01)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives
door: Peter Mohr, et al.
Gepubliceerd in: (2025-03-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
door: Karam Khaddour, et al.
Gepubliceerd in: (2021-06-01)

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
door: Igor V. Samoylenko, et al.
Gepubliceerd in: (2024-10-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
door: Adi Kartolo, et al.
Gepubliceerd in: (2022-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
door: Simeng Zhang, et al.
Gepubliceerd in: (2023-01-01)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
door: Clara So, et al.
Gepubliceerd in: (2022-05-01)

Braf protein mutation and its significancy within patients with melanoma
door: Julia Kuchnicka, et al.
Gepubliceerd in: (2022-08-01)

Treatment of Advanced Melanoma: Past, Present and Future
door: Taku Fujimura, et al.
Gepubliceerd in: (2020-09-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
door: Elodie Long-Mira, et al.
Gepubliceerd in: (2022-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
door: Walid Shalata, et al.
Gepubliceerd in: (2023-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
door: Nakul Dar, et al.
Gepubliceerd in: (2023-08-01)

Tyrosine kinase inhibitors via nasogastric tube may resolve severe ileus secondary to melanoma: A case report
door: Lena Groennendijk, et al.
Gepubliceerd in: (2022-06-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
door: Francesco Serra, et al.
Gepubliceerd in: (2021-08-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
door: O. I. Kit, et al.
Gepubliceerd in: (2016-06-01)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
door: Sim Vermeulen, et al.
Gepubliceerd in: (2021-04-01)